NeoStem, Inc. (NYSE Amex: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need and holds the exclusive, worldwide license to VSEL(TM) technology that uses very small embryonic-like stem cells isolated from peripheral blood, announced today that an abstract authored by NeoStem-affiliated scientists was presented in a poster presentation at the prestigious American Society of Hematology (ASH) Annual Meeting in New Orleans on December 5, 2009.
Dr. Robin Smith, M.D., MBA, NeoStem's Chief Executive Officer, said, "This week the National Institutes of Health approved the first 13 human embryonic stem cell lines for use in NIH-funded research so we are excited to share the news that there are actually adult stem cells that share many of the morphological characteristics of embryonic stem cells, removing risk of serious graft versus host disease or tissue rejection that can occur when the source of cells used for regenerative purposes is from a donor other than the patient receiving the stem cells. We are very proud that the significance of our very small embryonic-like stem cell research has been recognized by the prestigious American Society of Hematology. This is an important endorsement of the scientific advances that NeoStem is sponsoring in the field of adult stem cell research."
Abstracts selected for ASH poster presentation feature the latest research in the field and are chosen through blind scoring and a peer-review process as the most outstanding among the thousands submitted for the annual meeting. The NeoStem study that shows the successful mobilization of very small embryonic-like stem cells from the bone marrow to peripheral blood, was presented in Poster Session I on December 5th.
The authors of the abstract included: